XML 29 R16.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
We are currently developing therapies for the treatment of hematologic malignancies. To date, our only source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.
For the three months ended March 31, 2025, we have identified one operating and reportable segment. We define our operating segments based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker or CODM to analyze financial performance, make decisions, and allocate resources. Our Interim President and Chief Executive Officer is the CODM.
The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet. All long-lived assets are held in the United States.
Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability. The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2025 and 2024:
MARCH 31,
2025		MARCH 31,
2024
Revenues:
    Product revenue, net$39.4 $— 
    Royalties0.2 0.3 
Total revenues$39.6 $0.3 
Operating expenses:
Cost of goods sold1.2 — 
Research and development
     Research and clinical expenses13.7 16.4 
     Chemistry, manufacturing, and control expenses1.5 11.2 
Selling, general and administrative
     Commercial expenses20.0 11.3 
Other segment expenses*19.9 17.5 
Total operating expenses$56.3 $56.4 
Loss from operations(16.7)(56.1)
Total interest and other income (expense)(3.1)0.7 
Net loss$(19.8)$(55.4)